Fig. 1

Flowchart of Patients inclusion and exclusion. Patients with pathologically diagnosed gastric adenocarcinoma or adenocarcinoma of the esophagogastric junction, who underwent neoadjuvant therapy and radical gastrectomy, and who were tested for ah status of Helicobacter pylori infection prior to treatment during the period January 1, 2014, to July 1, 2024, were included in the study